<DOC>
	<DOC>NCT02065011</DOC>
	<brief_summary>Primary Objective: To evaluate the long-term safety and tolerability of UshStat® in patients with Usher syndrome type 1B Secondary Objective: To assess long-term safety and biological activity of UshStat®</brief_summary>
	<brief_title>A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Usher Syndromes</mesh_term>
	<criteria>Provide signed and dated written informed consent (and if appropriate assent) and any locally required authorization eg, Health Insurance Portability and Accountability Act (HIPAA). Must have been enrolled in Protocol TDU13600 Must have received a subretinal injection of UshStat® Did not receive UshStat® as part of the TDU13600 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>